The discovery of NTRK-associated gene fusions has led to the development of FDA-approved targeted therapies, for example, larotrectinib and entrectinib, which have shown efficacy in multiple cancer types by providing personalized treatment options.16,26,47 However, in Poland, Trk inhibitor treatment has been reimbursed only since July 1, 2023. Here, NTRK1 is linked to cancer.